Cite
HARVARD Citation
Van Den Bent, M. et al. (2020). INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-oncology. 22 (5), pp. 684-693. [Online].